# XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

> **NCT00226668** · PHASE3 · WITHDRAWN · sponsor: **Celtic Pharma Development Services** · enrollment: 120 (estimated)

## Conditions studied

- Brain Edema
- Brain Tumor

## Interventions

- **DRUG:** hCRF
- **DRUG:** placebo hCRF

## Key facts

- **NCT ID:** NCT00226668
- **Lead sponsor:** Celtic Pharma Development Services
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-01
- **Primary completion:** —
- **Final completion:** 2008-01
- **Target enrollment:** 120 (ESTIMATED)
- **Why stopped:** Alternate study projected to assess imaging endpoints versus clinical endpoints.
- **Last updated:** 2008-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00226668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00226668, "XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00226668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*